|
|
Volumn 343, Issue , 2011, Pages
|
|
FDA committee votes to withdraw bevacizumab for breast cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
BREAST TUMOR;
DISEASE FREE SURVIVAL;
DRUG RECALL;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NOTE;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
SAFETY-BASED DRUG WITHDRAWALS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 80052674045
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.d4244 Document Type: Note |
|
Times cited : (23)
|
|
References (0)
|
